The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 04, 2019

Filed:

Sep. 01, 2017
Applicants:

Janssen Vaccines & Prevention B.v., Leiden, NL;

Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD (US);

The United States of America, As Represented BY the Secretary of the Army, Fort Datrick, MD (US);

Inventors:

Frank Tomaka, Titusville, NJ (US);

Maria Grazia Pau, Leiden, NL;

Johanna Schuitemaker, Amstelveen, NL;

Dan Barouch, Newton, MA (US);

Jintanat Ananworanich, Rockville, MD (US);

Merlin Robb, Silver Spring, MD (US);

Nelson L. Michael, Silver Spring, MD (US);

Jerome Kim, Silver Spring, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/21 (2006.01); C07K 14/005 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61P 31/18 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 39/12 (2013.01); A61P 31/18 (2018.01); C12N 7/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/24043 (2013.01); C12N 2710/24143 (2013.01); C12N 2740/16021 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16171 (2013.01); C12N 2740/16234 (2013.01); C12N 2740/16271 (2013.01);
Abstract

Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.


Find Patent Forward Citations

Loading…